A Phase 1 interventional study of Ramucirumab and Pembrolizumab in Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction and Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 1, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 46th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2015, is one of 28 in phase 1, and was the 111th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
disease or locally advanced, unresectable disease.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with gastroesophageal junction (GEJ) cancer \[Second-Third Line (L)\] received 8 milligrams per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 for every 3 weeks (Q3W) of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab
Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Participants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.
Drug: Ramucirumab · Drug: Pembrolizumab
Administered IV
Also known as: LY3009806, IMC-1121B, Cyramza
Administered IV
Also known as: MK3475
Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
DLT is defined as an Adverse Event (AE) that is likely related to study medication or combination,and fulfills any one of following criteria:Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade (Gr) 3 and 4 nonlaboratory toxicity (tox),Any Gr 3 or 4 laboratory value if medical intervention is required to treat participant (pt) or abnormality persists for \>1 week;Hematologic tox:Gr 4 toxicity lasting ≥ 7 days,or Gr 3 thrombocytopenia if associated with bleeding and requires platelet transfusion,or Febrile neutropenia Gr 3 or Gr 4;GR 5 tox (death);Any toxicity that is possibly related to study treatment that requires withdrawal of pt from study during Cycle 1,A delay of \> 14 days due to persistent Grade ≥ 2 toxicities in initiating Cycle 2,with exception of Grade 2 fatigue;Any infusion or hypersensitivity reactions are NOT a DLT. A summary of other nonserious AEs and all Serious AEs,regardless of causality is located in Reported Adverse Event section.
Time frame: Cycle 1 (21 Days)
Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Measured Progressive Disease (Up to 24 Months)
Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. Participants who do not have any postbaseline tumor response assessments for any reason were considered.
Time frame: Baseline to Measured Progressive Disease (Up to 24 Months)
Phase 1a and 1b: Duration of Response (DoR)
The duration of response is defined only for responders (patients with a confirmed CR or PR). It is measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, DoR will be censored at the date of the last complete objective progression-free disease assessment (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 24 Months)
Phase 1a and 1b: Time to First Response (TTR)
TTR is defined as the time from the date of first study treatment until the first evidence of a confirmed CR or PR.
Time frame: Baseline to Date of CR or PR (Up to 24 Months)
Phase 1a and 1b: Progression Free Survival (PFS)
PFS is defined as the time from the date of first study treatment until the date of the first observed radiographically documented progressive disease (PD) or death due to any cause, whichever is earlier. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
Time frame: Baseline to PD or Death of Any Cause (Up to 24 Months)
Phase 1a and 1b: Overall Survival (OS)
The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.
Time frame: Baseline to Death from Any Cause (Up to 24 Months)
Phase 1a and 1b: Pharmacokinetics (PK): Minimum Trough Concentration (Cmin) of Ramucirumab
PK: Cmin of Ramucirumab following administration every 3 weeks.
Time frame: Phase 1a (Gastric-GEJ or BTC participants (pts)): Week (Wk) 1, 3, 6 and 9; Phase 1a (Gastric, NSCLC, or urothelial pts): Wk 3, 6, 9 and 12; Cohort A, A1, A2: Wk 1, 3, 6, 9, 12, 18, 19 and 24; Cohort B,C,D,E: Wk 3, 6, 9, 12, 18, 19 and 24
This study has Phase 1a (dose-limiting toxicity \[DLT\] observation) and expansion Phase 1b (safety and preliminary efficacy) included participants with 2 dosing schedules: Schedule 1: gastroesophageal junction (GEJ) cancer (Cohorts A, A2) and biliary tract cancer (Cohorts A1); Schedule 2: Gastric-GEJ cancer (Cohort B), nonsmall cell lung cancer (NSCLC) (Cohorts C, E), and urothelial cancer (Cohort D).
| Milestone | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|---|
| Started | 24 | 26 | 29 | 17 | 28 | 24 | 27 |
| Received at least one dose of study drug | 24 | 26 | 28 | 17 | 27 | 24 | 26 |
| Phase 1a | 8 | 0 | 0 | 0 | 3 | 0 | 0 |
| Phase 1b | 16 | 26 | 28 | 17 | 24 | 24 | 26 |
| Completed | 0 | 1 | 4 | 1 | 7 | 0 | 8 |
| Not completed | 24 | 25 | 25 | 16 | 21 | 24 | 19 |
| Withdrew: Death | 4 | 1 | 0 | 3 | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 3 | 5 | 1 | 1 | 0 | 2 |
| Withdrew: Progressive disease | 20 | 20 | 13 | 10 | 13 | 17 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 1 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 3 | 0 | 4 | 3 | 3 |
| Withdrew: Enrolled but never treated | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
DLT is defined as an Adverse Event (AE) that is likely related to study medication or combination,and fulfills any one of following criteria:Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade (Gr) 3 and 4 nonlaboratory toxicity (tox),Any Gr 3 or 4 laboratory value if medical intervention is required to treat participant (pt) or abnormality persists for \>1 week;Hematologic tox:Gr 4 toxicity lasting ≥ 7 days,or Gr 3 thrombocytopenia if associated with bleeding and requires platelet transfusion,or Febrile neutropenia Gr 3 or Gr 4;GR 5 tox (death);Any toxicity that is possibly related to study treatment that requires withdrawal of pt from study during Cycle 1,A delay of \> 14 days due to persistent Grade ≥ 2 toxicities in initiating Cycle 2,with exception of Grade 2 fatigue;Any infusion or hypersensitivity reactions are NOT a DLT. A summary of other nonserious AEs and all Serious AEs,regardless of causality is located in Reported Adverse Event section.
| participants | Cohort A | Cohort C |
|---|---|---|
| Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 1 | 0 |
Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Percentage of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] | 7.3 (1.5 to 19.9) | 3.8 (0.1 to 19.6) | 25.0 (10.7 to 44.9) | 29.6 (13.8 to 50.2) | 12.5 (2.7 to 32.4) | 42.3 (23.4 to 63.1) |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. Participants who do not have any postbaseline tumor response assessments for any reason were considered.
| percentage of participants | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)] | 51.2 (35.1 to 67.1) | 38.5 (20.2 to 59.4) | 67.9 (47.6 to 84.1) | 85.2 (66.3 to 95.8) | 50.0 (29.1 to 70.9) | 84.6 (65.1 to 95.6) |
The duration of response is defined only for responders (patients with a confirmed CR or PR). It is measured from the date of first evidence of a confirmed CR or PR to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, DoR will be censored at the date of the last complete objective progression-free disease assessment (CR or PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Duration of Response (DoR) | 6.7 (4.4 to 17.5) | 6.0 (NA to NA) | NA (9.7 to NA) | NA (11.1 to NA) | 8.3 (4.6 to 16.8) | NA (5.2 to NA) |
TTR is defined as the time from the date of first study treatment until the first evidence of a confirmed CR or PR.
| months | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Time to First Response (TTR) | 1.4 (1.4 to 4.1) | 2.7 (NA to NA) | 2.7 (1.3 to 2.8) | 2.1 (1.3 to 3.0) | 2.8 (1.3 to 5.5) | 1.4 (1.2 to 3.0) |
PFS is defined as the time from the date of first study treatment until the date of the first observed radiographically documented progressive disease (PD) or death due to any cause, whichever is earlier. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.
| months | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Progression Free Survival (PFS) | 2.5 (1.5 to 4.2) | 1.6 (1.4 to 2.8) | 5.6 (2.7 to 11.5) | 9.7 (4.6 to 27.6) | 1.9 (1.2 to 2.8) | 9.3 (4.0 to NA) |
The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.
| months | Cohort A and B | Cohort A1 | Cohort A2 | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|
| Phase 1a and 1b: Overall Survival (OS) | 5.9 (4.4 to 10.6) | 6.4 (4.2 to 13.3) | 14.6 (5.4 to NA) | 26.2 (11.8 to NA) | 6.4 (2.5 to 18.7) | NA (13.2 to NA) |
PK: Cmin of Ramucirumab following administration every 3 weeks.
| micrograms/milliliter (μg/mL) | Phase 1a: Gastric-GEJ or BTC | Phase 1 a: Gastric, NSCLC, or Urothelial Patients | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | 50.9 ± 24 | — | 44.2 ± 28 | 45.2 ± 41 | 45.9 ± 23 | — | — | — | — |
| Week 3 | 52 ± 29 | 20.9 ± 35 | 40 ± 48 | 44.1 ± 57 | 45.2 ± 32 | 13.3 ± 93 | 22.5 ± 62 | 20.9 ± 54 | 15.6 ± 70 |
| Week 6 | 69 ± 29 | NA ± NA | 79.8 ± 30 | 69.1 ± 68 | 61 ± 38 | 25.7 ± 74 | 33.8 ± 68 | 23.3 ± 102 | 19.3 ± 115 |
| Week 9 | NA ± NA | 32.7 ± 20.6 | 72.8 ± 46 | 94.3 ± 40 | 78.8 ± 31 | 32.7 ± 60 | 40.1 ± 63 | 34.8 ± 73 | 28.6 ± 90 |
| Week 12 | — | NA ± NA | 89.3 ± 35 | NA ± NA | 80.2 ± 38 | 36.8 ± 48 | 47.1 ± 45 | 34.9 ± 141 | 26.3 ± 89 |
| Week 18 | — | — | 92.4 ± 71 | NA ± NA | 87.6 ± 48 | 52.7 ± 45 | 44.4 ± 31 | 52.6 ± 36 | 37.1 ± 66 |
| Week 19 | — | — | 149 ± 69 | NA ± NA | 120 ± 34 | — | — | — | — |
| Week 24 | — | — | 116 ± 83 | NA ± NA | 95.7 ± 27 | 43.6 ± 40 | 45 ± 29 | NA ± NA | 42.1 ± 87 |
Collected over Baseline Up to 5.9 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 21/24 (87.5%) | 10/24 (41.7%) | 23/24 (95.8%) |
| Cohort A1 | 19/26 (73.1%) | 15/26 (57.7%) | 26/26 (100%) |
| Cohort A2 | 17/28 (60.7%) | 16/28 (57.1%) | 28/28 (100%) |
| Cohort B | 13/17 (76.5%) | 10/17 (58.8%) | 16/17 (94.1%) |
| Cohort C | 16/27 (59.3%) | 15/27 (55.6%) | 27/27 (100%) |
| Cohort D | 18/24 (75%) | 16/24 (66.7%) | 24/24 (100%) |
| Cohort E | 9/26 (34.6%) | 14/26 (53.8%) | 26/26 (100%) |
| Event | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 3/24 | 2/26 | 1/28 | 2/17 | 0/27 | 1/24 | 1/26 |
| ColitisGastrointestinal disorders | 0/24 | 1/26 | 2/28 | 2/17 | 0/27 | 2/24 | 0/26 |
| DysphagiaGastrointestinal disorders | 1/24 | 0/26 | 1/28 | 2/17 | 0/27 | 0/24 | 0/26 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 0/26 | 0/28 | 2/17 | 0/27 | 1/24 | 0/26 |
| Urinary tract infectionInfections and infestations | 0/24 | 0/26 | 3/28 | 1/17 | 0/27 | 0/24 | 0/26 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/24 | 0/26 | 2/28 | 1/17 | 0/27 | 0/24 | 0/26 |
| UrosepsisInfections and infestations | 0/24 | 0/26 | 1/28 | 0/17 | 0/27 | 2/24 | 0/26 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/24 | 1/26 | 1/28 | 0/17 | 1/27 | 0/24 | 1/26 |
| Acute myocardial infarctionCardiac disorders | 0/24 | 0/26 | 1/28 | 0/17 | 0/27 | 0/24 | 2/26 |
| Pericardial effusionCardiac disorders | 0/24 | 0/26 | 0/28 | 0/17 | 0/27 | 0/24 | 2/26 |
| Event | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 14/24 | 9/26 | 19/28 | 9/17 | 10/27 | 11/24 | 9/26 |
| NauseaGastrointestinal disorders | 6/24 | 11/26 | 12/28 | 2/17 | 5/27 | 5/24 | 8/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/24 | 7/26 | 4/28 | 3/17 | 11/27 | 2/24 | 6/26 |
| DiarrhoeaGastrointestinal disorders | 4/24 | 9/26 | 11/28 | 6/17 | 8/27 | 7/24 | 8/26 |
| Decreased appetiteMetabolism and nutrition disorders | 8/24 | 7/26 | 9/28 | 4/17 | 10/27 | 8/24 | 4/26 |
| HypertensionVascular disorders | 4/24 | 9/26 | 10/28 | 4/17 | 9/27 | 7/24 | 6/26 |
| Abdominal painGastrointestinal disorders | 4/24 | 9/26 | 5/28 | 4/17 | 3/27 | 4/24 | 2/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/24 | 4/26 | 3/28 | 0/17 | 9/27 | 2/24 | 3/26 |
| Intermenstrual bleedingReproductive system and breast disorders | 0/7 | 1/18 | 0/7 | 1/3 | 0/6 | 0/10 | 0/14 |
| HypothyroidismEndocrine disorders | 3/24 | 4/26 | 1/28 | 2/17 | 8/27 | 2/24 | 2/26 |
All enrolled participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 56.0 (24.0 to 78.0) | 62.5 (36.0 to 78.0) | 63.0 (31.0 to 83.0) | 61.0 (28.0 to 73.0) | 65.0 (34.0 to 82.0) | 63.0 (45.0 to 87.0) | 63.0 (42.0 to 85.0) | 61.28 (24.0 to 87.0) |
| Sex: Female, Male(Participants) | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 18 | 7 | 3 | 6 | 10 | 14 | 65 |
| Male | 17 | 8 | 21 | 14 | 21 | 14 | 12 | 107 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 3 | 2 | 3 | 4 | 0 | 20 |
| Not Hispanic or Latino | 20 | 19 | 16 | 12 | 21 | 10 | 25 | 123 |
| Unknown or Not Reported | 2 | 1 | 9 | 3 | 3 | 10 | 1 | 29 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 3 | 0 | 0 | 1 | 0 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 4 |
| White | 19 | 23 | 17 | 16 | 26 | 22 | 22 | 145 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 10 | 0 | 0 | 2 | 3 | 18 |
| Region of Enrollment(Participants) | Cohort A | Cohort A1 | Cohort A2 | Cohort B | Cohort C | Cohort D | Cohort E | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 3 | 2 | 11 | 8 | 4 | 8 | 11 | 47 |
| United Kingdom | 15 | 11 | 7 | 5 | 2 | 5 | 6 | 51 |
| France | 2 | 3 | 7 | 1 | 8 | 2 | 2 | 25 |
| Germany | 0 | 1 | 1 | 0 | 0 | 1 | 5 | 8 |
| Spain | 4 | 9 | 2 | 3 | 13 | 8 | 2 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Aug 2018, 37 months.
Results were first posted in Jul 2024, 5 years 11 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 37 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Pembrolizumab
Carcinoma, Non-Small-Cell Lung →